Joel Schlessinger M.D.

In a study published by the British Journal of Dermatology, researchers found Tofacitinib to be an effective treatment for moderate to severe chronic plaque psoriasis. Joel Schlessinger MD and his staff at the Advanced Skin Research Center were an integral part of the study, conducting research over a 56-week period.

The study conducted by Joel Schlessinger MD compared Tofacitinib withdrawal with patients who continued medication.

Tofacitinib is an oral Janus kinase inhibitor that is being studied for the treatment of moderate to severe plaque psoriasis. In the study conducted by Joel Schlessinger MD and others, patients were first treated with Tofacitinib to test their responses to the medication. After the initial treatment, one group of patients continued to receive the initial dose of Tofacitinib while another group received a placebo. The study found that continuously treated patients maintained better results than those who received the placebo.

Joel Schlessinger and his staff at the Advanced Skin Research Center conduct numerous studies each year.

Under the direction of Joel Schlessinger MD, the Advanced Skin Research Center has been active in the advancement of skin care and skin health since 1993. This established dermatology research center provides quality clinical research data to pharmaceutical companies around the world. Each year, the center investigates new medications and treatments for a wide range of skin conditions, as well as cosmetic procedures.

Do you have a question for Joel Schlessinger MD? Share with us in the comments.